AVDL
Avadel Pharmaceuticals plc
1W: +0.1%
1M: +0.6%
3M: +43.7%
1Y: +104.5%
3Y: +208.7%
5Y: +207.4%
$21.64
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range6.38-23.57
Volume35,016,239
Avg Volume2,415,222
Beta1.31
Dividend—
Analyst Ratings
Company Info
CEOGregory J. Divis Jr.
Employees188
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date1996-06-07
Websiteavadel.com
10 Earlsfort Terrace
Dublin 2
IE
Dublin 2
IE
353 1 901 5201
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Weiss Asset Manageme | S-Sale | 11,112,052 | $21.00 | 2026-02-13 |
| Rodriguez Susan | D-Return | 300,000 | $9.59 | 2026-02-12 |
| Thornton Peter J. | D-Return | 115,060 | $21.00 | 2026-02-12 |
| Thornton Peter J. | D-Return | 60,000 | $2.03 | 2026-02-12 |
| Thornton Peter J. | D-Return | 42,000 | $8.48 | 2026-02-12 |